Filing summary
Filing identity and period: The supplied filing is Organovo Holdings, Inc. (Nasdaq: ONVO), not Vivosim Labs, Inc. It is a Form 10-K for the fiscal year ended March 31, 2023, with comparative results for the year ended March 31, 2022—not a 2021 Q4 filing. The report was signed July 13, 2023.
Business context
Organovo is a biotechnology company developing 3D human tissue models intended to help identify disease targets and support drug discovery. Its primary focus is inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. In March 2023, it acquired Metacrine’s FXR program, including two clinically tested compounds and more than 2,000 discovery or preclinical compounds. The company reported no current revenue from academic research collaborations.
Financial performance and liquidity
| Metric | FY ended March 31, 2023 | FY ended March 31, 2022 |
|---|---|---|
| Revenue | $0.37 million | $1.50 million |
| Research and development expense | $8.89 million | $3.32 million |
| Selling, general and administrative expense | $9.22 million | $9.66 million |
| Operating loss | $17.73 million | $11.48 million |
| Net loss | $17.26 million | $11.45 million |
| Net loss per share | $1.98 | $1.32 |
| Cash used in operating activities | $12.41 million | $8.45 million |
At March 31, 2023, cash and cash equivalents were $15.30 million, current assets $17.05 million, current liabilities $3.67 million, and working capital $13.3 million. Accumulated deficit was $325.0 million. Total liabilities were $4.98 million, including $1.81 million of operating lease liabilities; the balance sheet reports no borrowing debt. Revenue was entirely royalty revenue, and the company had one royalty licensee. No meaningful gross-margin measure is presented.
Material changes and unusual items
- Revenue fell 75%, from $1.50 million to $0.37 million. The prior-year figure included a $1.50 million upfront payment for a patent license; FY2023 revenue was sales-based royalties.
- R&D expense rose 168%, largely as development activity expanded. It included $4.0 million of acquired in-process R&D related to the Metacrine FXR program; $2.0 million was paid during FY2023 and $2.0 million was accrued for payment in the following fiscal year.
- SG&A declined 5%, principally because patent litigation costs were lower after the dispute with BICO Group was settled in FY2022.
- Interest income increased to $0.45 million from $0.01 million, primarily reflecting higher interest rates.
- Operating cash use increased by $3.96 million year over year. The company ended the year with substantially less cash than the prior year.
Outlook, risks and contingencies
Management forecast FY2024 operating expenses of $12 million to $14 million. It stated that substantial additional funding would be needed to support future operations and concluded that substantial doubt existed about the company’s ability to continue as a going concern for at least one year after the financial statements were issued. The auditor’s report likewise included a going-concern explanatory paragraph. The statements were prepared on a going-concern basis and contain no adjustments for a possible inability to continue operations.
The business plan depends on an unproven drug-discovery strategy and the ability to develop useful disease models, identify drug candidates, secure partnerships, obtain future financing, and ultimately achieve regulatory and commercial success. Potential equity financing could dilute shareholders; financing may not be available on acceptable terms. Other material risks include reliance on suppliers for human cells, competition, intellectual-property challenges, and possible Nasdaq listing and stock-price volatility. The company reported no material legal proceedings and no recorded loss-contingency accruals. It reported effective disclosure controls and effective internal control over financial reporting as of March 31, 2023.
Important facts for investors to verify
- Confirm the filing belongs to the intended issuer and period: the source is Organovo Holdings’ FY2023 10-K, not Vivosim Labs’ 2021 Q4 filing.
- Review the company’s cash runway assumptions, projected spending, and financing plans against the going-concern disclosures; stated liquidity does not remove the disclosed substantial doubt.
- Verify the status, transfer completion, and development plans for the acquired FXR assets, including the remaining $2.0 million purchase payment and potential Salk milestone and royalty obligations.
- Assess the source and durability of royalty revenue, which came from a single licensee, and note that FY2022 revenue included a nonrecurring upfront license payment.
- Check current share count, financing capacity, and potential dilution. The filing reported 8,716,906 shares outstanding at March 31, 2023 and approximately $28.3 million remaining under the ATM program, subject to applicable offering limits.